A follow-up study further indicated that treatment with brusatol could augment the sensitivity of anticancer drug cytarabine and daunorubicin to acute myeloid leukemia (AML) cells, and reduce its colony formation ability by downregulating the protein expression of Nrf2. The gene discussed is NFE2L2; the disease is acute myeloid leukemia.